JCAR-024 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JCAR-024’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JCAR-024 is under development for the treatment of ROR-1 expressing chronic lymphocytic leukemia, refractory mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), stage IV and solid tumors like non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and obesity. The therapeutic candidate consists of lentiviral vector acts by targeting cells which express receptor tyrosine kinase-like orphan receptor 1 (ROR1). It is developed based on the CAR (chimeric antigen receptor) technology.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of JCAR-024’s drug-specific PTSR and LoA scores, buy the report here.